Literature DB >> 18089867

Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study.

Murielle E L Mauer1, Martin J B Taphoorn, Andrew Bottomley, Corneel Coens, Fabio Efficace, Marc Sanson, Alba A Brandes, Carin C D van der Rijt, Hans J J A Bernsen, Marc Frénay, Cees C Tijssen, Denis Lacombe, Martin J van den Bent.   

Abstract

PURPOSE: This is one of a few studies that have explored the value of baseline symptoms and health-related quality of life (HRQOL) in predicting survival in patients with brain cancer. PATIENTS AND METHODS: Baseline HRQOL scores (from the European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire C30 and the EORTC Brain Cancer Module) were examined in 247 patients with anaplastic oligodendrogliomas to determine the relationship with overall survival by using Cox proportional hazards regression models. Refined techniques as the bootstrap resampling procedure and the computation of C indexes and R2 coefficients were used to explore the stability of the models as well as better assess the potential benefit of using HRQOL to predict survival in clinical practice and research.
RESULTS: Classical analysis controlled for major clinical prognostic factors selected emotional functioning (P = .0016), communication deficit (P = .0261), future uncertainty (P = .0481), and weakness of legs (P = .0001) as statistically significant prognostic factors of survival. However, several issues question the validity of these findings and no single model was found to be preferable over all others. C indexes, which estimate the probability of a model to correctly predict which patient among a randomly chosen pair of patients will survive longer, and R2 coefficients, which measure the proportion of variability explained by the model, did not exhibit major improvement when adding selected or all HRQOL scores to clinical factors.
CONCLUSION: While classical techniques lead to positive results, more refined analyses suggest that baseline HRQOL scores add relatively little to clinical factors to predict survival. These results may have implications for future use of HRQOL as a prognostic factor for patients with cancer.

Entities:  

Mesh:

Year:  2007        PMID: 18089867     DOI: 10.1200/JCO.2007.11.1476

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  26 in total

Review 1.  Review on quality of life issues in patients with primary brain tumors.

Authors:  Martin J B Taphoorn; Eefje M Sizoo; Andrew Bottomley
Journal:  Oncologist       Date:  2010-05-27

2.  Patterns of care and survival for glioblastoma patients in the Veterans population.

Authors:  Robert T Arrigo; Maxwell Boakye; Stephen L Skirboll
Journal:  J Neurooncol       Date:  2011-09-01       Impact factor: 4.130

3.  Methodological issues in designing and reporting health-related quality of life in cancer clinical trials: the challenge of brain cancer studies.

Authors:  Fabio Efficace; Martin Taphoorn
Journal:  J Neurooncol       Date:  2012-02-25       Impact factor: 4.130

4.  PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion.

Authors:  J Lee Villano; Patrick Y Wen; Eudocia Q Lee; Lakshmi Nayak; David A Reardon; Myrna R Rosenfeld
Journal:  J Neurooncol       Date:  2013-03-12       Impact factor: 4.130

Review 5.  Fatigue among patients with brain tumors.

Authors:  Arash Asher; Jack B Fu; Charlotte Bailey; Jennifer K Hughes
Journal:  CNS Oncol       Date:  2016-03-17

Review 6.  Factors influencing quality of life in adult patients with primary brain tumors.

Authors:  Rakesh Jalali; Debnarayan Dutta
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

7.  A longitudinal study of the role of patient-reported outcomes on survival prediction of palliative cancer inpatients in Taiwan.

Authors:  Jing-An Chang; Chia-Chin Lin
Journal:  Support Care Cancer       Date:  2009-02-12       Impact factor: 3.603

8.  Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing.

Authors:  Lee W Jones; Rachel-Rose Cohen; Stephanie K Mabe; Miranda J West; Annick Desjardins; James J Vredenburgh; Allan H Friedman; David A Reardon; Emily Waner; Henry S Friedman
Journal:  J Neurooncol       Date:  2009-02-11       Impact factor: 4.130

9.  Neurocognitive training in patients with high-grade glioma: a pilot study.

Authors:  Marco Ronald Hassler; Katarzyna Elandt; Matthias Preusser; Johann Lehrner; Petra Binder; Karin Dieckmann; Andrea Rottenfusser; Christine Marosi
Journal:  J Neurooncol       Date:  2009-09-10       Impact factor: 4.130

Review 10.  Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008.

Authors:  Ali Montazeri
Journal:  Health Qual Life Outcomes       Date:  2009-12-23       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.